HOEVELAKEN, The Netherlands, Sept. 25, 2024 /PRNewswire/ — OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and…
Other News
FineHeart Appoints André-Jacques Auberton-Hervé Member of the Board of Directors
BORDEAUX, France–(BUSINESS WIRE)–FineHeart S.A, a clinical-stage medtech company developing breakthrough solutions for cardiology, is pleased to announce the appointment of André-Jacques Auberton-Hervé to its Board of Directors. “The exceptional career of André-Jacques, a visionary industrialist, is inspirational for the whole team. We sincerely thank him for the trust he has […]
InfoBionic.Ai Announces Inclusion of MoMe ARC Solution in Connection Hub on Epic Showroom
BOSTON–(BUSINESS WIRE)–InfoBionic.Ai, an innovative digital health company providing industry-validated highest quality ECG and AI-powered diagnostic remote patient monitoring solutions, announces the inclusion of its MoMe.net ambulatory ECG monitoring system in Connection Hub on Epic Showroom. “Our inclusion in Showroom marks a significant step in our goal of empowering providers with innovative […]
HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced the appointment of Lance Myers, PhD, a pioneer in digital health data analytics and body-worn biosensor technologies, as Chief Artificial Intelligence (AI) Scientist. In this […]
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented at the CHEST 2024 Annual Meeting hosted by the American College of Chest Physicians taking place October […]
Toro Neurovascular Announces First Patient Treated in Clinical Trial for SuperBore Aspiration Catheter for Acute Ischemic Stroke
September 24, 2024 10:00 AM Eastern Daylight Time IRVINE, Calif.–(BUSINESS WIRE)–Toro Neurovascular, an innovative medical device company, is excited to announce the successful treatment of the first patient using its Toro 88 SuperBore Aspiration Catheter as part of a first-in-man clinical study. The procedure, performed by esteemed neurosurgeon Nobuyuki Sakai, […]
Fzata, Inc. Announces Multi-million Dollar NIH Grant
HALETHORPE, Md., Sept. 24, 2024 /PRNewswire/ — Fzata, Inc. is pleased to announce a five-year UG3/UH3 non-dilutive grant (UG3NS135350) of up to $7 million, plus in-kind contributions, awarded by the NIH National Institute of Neurological Disorders and Stroke (NINDS). Grant participants…
Cardiology Experts Warn of Rising Heart Failure Rates and Worsening Disparities in New 2024 Report
Shocking Increase in Heart Failure Prevalence, Mortality, and Impact on Younger Patients WASHINGTON, Sept. 24, 2024 /PRNewswire/ — The latest findings on heart failure (HF) published by Heart Failure Society of America (HFSA) reveal a concerning rise in the prevalence, mortality, and…
Annals of Family Medicine: Systematic Review Highlights Promise of High-Sensitivity Troponin in Diagnosing Acute Coronary Syndrome in Primary Care Settings
PROVIDENCE, R.I., Sept. 24, 2024 /PRNewswire/ — Findings from a new systematic review, titled “Chest Pain in Primary Care: A Systematic Review of Risk Stratification Tools to Rule Out Acute Coronary Syndrome,” published in Annals of Family Medicine, suggest that high-sensitivity troponin…
Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA-



